-
6/6/2024
Rapport Therapeutics，Inc.，aclinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders，announced the pricing of its inital public offering of 8000，000shares of its common stock at a public offering price of$17.00per share。
-
6/4/2024
Bitterroot Bio，apioneering biotechnology company focused on developing innovative medicines in the field of cardio-immunology，announced the appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secrety。
-
5/29/2024
Georgiamune Inc.，a privately held，clinical-stage biotechnology company，announced the clearance of its second Investigational New Drug application by the U.S.Food and Drug Administration for GIM-531，a first-in-class oral treatment that selectively targets T-regulatory cells and spares others and sucells and imance CD。
-
5/28/2024
CARGO Therapeutics，Inc.，aclinical-stage biotechnology company positioned to advance next generation，potentially curative cell therapies for cancer patients，announced that the company will be participating in the following investor conferences。
-
5/28/2024
CARGO Therapeutics，Inc.announced that it has entered into a securities purchase agreement fora private investment in public equity financing that is expected to result in gross proceeds of approximately$110.0million，before deducting placement agent fees and other expenses。
-
Orna Therapeutics announced Thursday it is acquiring ReNAgade Therapeutics，which launched in May2023 with$300 million in Series A financing and is on BioSpace’s NextGen Class of 2024 startups to watch this year。
-
5/15/2024
Apogee Therapeutics，Inc.announced that it has initiated dosing in the Phase2trial of APG777 in patients with moderate-to-severe atopic deratitis。
-
5/13/2024
Apogee Therapeutics，Inc.，aclinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermattis，chronic obstructive pulmonary disease，asthma and other inflammatory and immunology indications，reported pipeline highlights and first quarter financial。
-
5/9/2024
KateTx debuted less than a year ago with a$51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures and an exclusive license of KT430to Astellas Pharmaceuticals for the treatment of X-linked myotubular myopathy。
-
5/6/2024
Apogee Therapeutics，Inc.announced that Michael Henderson，M.D.，Chief Executive Officer and Jane Pritchet Henderson，Chief Financial Officer，will participate in a fireside chat the 2024 Bank of America Healthcare Conference on Wednesday，May152024at3:40p.P.T/6:40。
-
4/27/2024
ReNAgade Therapeutics announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio，and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem。
-
4/18/2024
Initial Therapeutics Inc.has appointed Peter DiLaura as President and Chief Executive Officer and a member of the company's Board of Directors，effective immediately。
-
4/3/2024
Alterome Therapeutics，Inc.，a biopharmaceutical company pioneering the development of next generation，small molecule targeted therapies for the treatment of cancer，announced the closing of a$132 million Series B financing。
-
3/25/2024
Apogee Therapeutics，Inc.today announced that it has initiated dosing of healthy volunters in its first clinical trial for APG808，anovel subcutaneous（SQ）extended half-life monoclonal antibody（mAb）targeting IL-4Rα，which is being developed as a treatment for people living with moderate-to-severe COPD，asthma and other I&I diseases。
-
3/7/2024
Apogee Therapeutics，Inc.announced the pricing of its upsized previously announced underwritten public offering of 6774193 shares of common stock at a public offering price per share of$62.00。
-
3/5/2024
Apogee Therapeutics，Inc.，aclinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermattis，chronic obstructive pulmonary disease，asthma and other inflammatory and immunology indications，reported pipeline highlights and fourth quiter and fusurefinarfor3。
-
3/5/2024
Bonum Therapeutics announced the first public presentation of preclinical data on its lead program，a conditionally active LAG3-IL2therapeutic。
-
3/5/2024
Apogee Therapeutics，Inc.announced that it has commenced an underwritten public offering of approximately$350.0 million of shares of its common stock。
-
2/28/2024
Rapport Therapeutics，Inc.today announced the appointment of Kathy Wilkinson as Chief People Officer。
-
1/16/2024
Rapport Therapeutics，Inc.announced the appointment of Terry-Ann Burrell to its Board of Directors。
